| Drug Name |
Diroximel fumarate |
| Drug ID |
BADD_D02550 |
| Description |
Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life.[A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS.[A187535]
Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225] |
| Indications and Usage |
Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults; specifically active secondary progressive disease and clinically isolated syndrome, as well as relapsing-remitting MS.[L9623,L9629,L9632] |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AX09 |
| DrugBank ID |
DB14783
|
| KEGG ID |
D11154
|
| MeSH ID |
Not Available
|
| PubChem ID |
73330464
|
| TTD Drug ID |
D0TD7J
|
| NDC Product Code |
71796-036; 66039-966; 69037-0059; 64406-020; 11722-067; 56125-700; 69766-086 |
| UNII |
K0N0Z40J3W
|
| Synonyms |
Not Available |
